
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is a pioneer and leader in the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management (LAAM), and its innovative product line, experienced management team, and strong sales force position the company for durable revenue growth and profitability in the years ahead. The recent launch of the CryoSPHERE MAX device and favorable clinical trial results for the BOxX-NoAF technology add to AtriCure's already strong product portfolio, and we believe the company's current valuation does not adequately reflect its potential for continued success and market share expansion.
Bears say
AtriCure is facing strong competition in the market and may struggle to gain widespread acceptance, impacting their operating results. Additionally, rising healthcare costs and potential changes in payors' policies towards coverage and reimbursement could harm the company's ability to sell their products. The company's success is also dependent on positive clinical data and meeting strict regulatory requirements, which may not always be achievable.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares